Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial.
Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial.
复制标题
DOI：
10.1371/journal.pone.0163716
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Broccoli Sprout Extract Trial Research Group
中科院分区：
文献类型：
--
作者：
Wise RA;Holbrook JT;Criner G;Sethi S;Rayapudi S;Sudini KR;Sugar EA;Burke A;Thimmulappa R;Singh A;Talalay P;Fahey JW;Berenson CS;Jacobs MR;Biswal S;Broccoli Sprout Extract Trial Research Group
COPD patients have high pulmonary and systemic oxidative stress that correlates with severity of disease. Sulforaphane has been shown to induce expression of antioxidant genes via activation of a transcription factor, nuclear factor erythroid-2 related factor 2 (Nrf2). This parallel, placebo-controlled, phase 2, randomized trial was conducted at three US academic medical centers. Patients who met GOLD criteria for COPD and were able to tolerate bronchoscopies were randomly assigned (1:1:1) to receive placebo, 25 μmoles, or 150 μmoles sulforaphane daily by mouth for four weeks. The primary outcomes were changes in Nrf2 target gene expression (NQ01, HO1, AKR1C1 and AKR1C3) in alveolar macrophages and bronchial epithelial cells. Secondary outcomes included measures of oxidative stress and airway inflammation, and pulmonary function tests. Between July 2011 and May 2013, 89 patients were enrolled and randomized. Sulforaphane was absorbed in the patients as evident from their plasma metabolite levels. Changes in Nrf2 target gene expression relative to baseline ranged from 0.79 to 1.45 and there was no consistent pattern among the three groups; the changes were not statistically significantly different from baseline. Changes in measures of inflammation and pulmonary function tests were not different among the groups. Sulforaphane was well tolerated at both dose levels. Sulforaphane administered for four weeks at doses of 25 μmoles and 150 μmoles to patients with COPD did not stimulate the expression of Nrf2 target genes or have an effect on levels of other anti-oxidants or markers of inflammation. Clinicaltrials.gov: NCT01335971.
登录
查看更多内容
影响因子：
3.7
作者：
Noah, Terry L.;Zhang, Hongtao;Jaspers, Ilona
通讯作者：
Jaspers, Ilona
影响因子：
4
作者：
Rahman, Irfan;MacNee, William
通讯作者：
MacNee, William
影响因子：
2.2
作者：
Bowler, Russell P;Barnes, Peter J;Crapo, James D
通讯作者：
Crapo, James D
DOI：
10.1158/1940-6207.capr-15-0290
发表时间：
2016-07
期刊：
Cancer prevention research (Philadelphia, Pa.)
影响因子：
--
作者：
Bauman JE;Zang Y;Sen M;Li C;Wang L;Egner PA;Fahey JW;Normolle DP;Grandis JR;Kensler TW;Johnson DE
通讯作者：
Johnson DE
影响因子：
15.9
作者：
Rangasamy, T;Cho, CY;Biswal, S
通讯作者：
Biswal, S